0000950170-22-017733.txt : 20220824 0000950170-22-017733.hdr.sgml : 20220824 20220824161701 ACCESSION NUMBER: 0000950170-22-017733 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220823 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20220824 DATE AS OF CHANGE: 20220824 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 221191750 BUSINESS ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 8-K 1 alna-20220823.htm 8-K 8-K
0001624658false00016246582022-08-232022-08-23

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2022

 

 

Allena Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38268

45-2729920

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

142-F North Road

Suite 150

 

Sudbury, Massachusetts

 

01776

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 467-4577

 

 

Newton Executive Park, Suite 202

Newton, Massachusetts 02462

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ALNA

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on August 25, 2021, Allena Pharmaceuticals, Inc. (the “Company” or “Allena”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between July 14, 2021 through August 24, 2021, its common stock had not maintained a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5550(a)(2).
 

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until February 21, 2022, to regain compliance with the Minimum Bid Price Requirement. On February 22, 2022 the Company applied to transfer its securities to The Nasdaq Capital Market and requested a second 180-day period to regain compliance with the Minimum Bid Price Requirement. On February 24, 2022, Nasdaq approved the Company’s request for a second 180-day period, or until August 22, 2022, to regain compliance with the Minimum Bid Price Requirement.


On August 23, 2022, the Company received a letter from the Staff indicating that (i) the Company has not regained compliance with the Minimum Bid Price Requirement, and (ii) failure to regain compliance with the Minimum Bid Price Requirement serves as a basis for delisting the Company’s securities from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel"). In the event the Company elects not to request a hearing, trading of the Company’s common stock will be suspended at the opening of business on September 1, 2022 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market.
 

The Company has until 4:00 p.m. Eastern Time on August 30, 2022 to request a hearing before the Panel at which hearing it can request continued listing pending its return to compliance with the Minimum Bid Price Requirement. Additionally, in order to be ultimately eligible for continued listing on The Nasdaq Capital Market, the Company would need to meet all other requirements for continued listing on The Nasdaq Capital Market. Any such hearing request would stay the suspension of trading and delisting of the Company’s common stock pending the conclusion of the hearing process and the expiration of any additional extension period granted by the Panel following the hearing. The Company is considering whether to request a hearing while it evaluates all of its available strategic alternatives, including a potential bankruptcy filing.
 

On August 4, 2022, the Company received stockholder approval to effect a reverse stock split, to be effected at the discretion of the Company’s board of directors at any time prior to December 31, 2022. The Company has delayed implementing the reverse stock split while it evaluates all of its available strategic alternatives, including a potential bankruptcy filing. If implemented, the Company expects that the reverse stock split, once effective, could enable the Company to regain compliance with the Minimum Bid Price Requirement. However, the Company may fail to meet other requirements for continued listing on the Nasdaq Capital Market. The outcome of any Panel hearing, if requested, is uncertain.
 

Forward-Looking Statements
 

This Current Report on Form 8-K release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning Allena’s ability to request a hearing before a Nasdaq Hearing Panel, and the outcome of any such hearing, Allena’s ability to implement the reverse stock split and satisfy the Minimum Bid Price Requirement and Allena’s ability to meet other requirements for continued listing on The Nasdaq Stock Market. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Additional risks and uncertainties include, but are not limited to: market and other conditions, the timing for completion of Allena’s clinical trials of its product candidates, risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of ALLN-346, and its ability to continue as a going concern; risks associated with Allena’s dependence on third parties; risks related to the COVID-19 coronavirus; risks associated with Allena’s ability to identify and consummate financing and strategic alternatives that yield additional value for shareholders; the timing, benefits and outcome of Allena’s strategic alternatives review process, including the determination of whether or not to pursue or consummate any strategic alternative, the structure, terms and specific risks and uncertainties associated with any potential strategic transaction, potential disruptions in Allena’s business and stock price as a result of its exploration, review and pursuit of strategic alternatives or the public announcement thereof and any decision or transaction resulting from such review. For a discussion of other risks and uncertainties,

 

 

and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Allena’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-K is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Allena Pharmaceuticals, Inc.

 

 

 

 

Date:

August 24, 2022

By:

/s/ Richard Katz

 

 

 

Richard Katz, M.D.
Chief Financial Officer

 

 

 EX-101.LAB 2 alna-20220823_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 3 alna-20220823_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 alna-20220823.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Aug. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 23, 2022
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity Central Index Key 0001624658
Entity Emerging Growth Company true
Securities Act File Number 001-38268
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One 142-F North Road
Entity Address, Address Line Two Suite 150
Entity Address, City or Town Sudbury
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01776
City Area Code (617)
Local Phone Number 467-4577
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
XML 6 alna-20220823_htm.xml IDEA: XBRL DOCUMENT 0001624658 2022-08-23 2022-08-23 0001624658 false 8-K 2022-08-23 Allena Pharmaceuticals, Inc. DE 001-38268 45-2729920 142-F North Road Suite 150 Sudbury MA 01776 (617) 467-4577 false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports alna-20220823.htm alna-20220823.xsd alna-20220823_lab.xml alna-20220823_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alna-20220823.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "alna-20220823.htm" ] }, "labelLink": { "local": [ "alna-20220823_lab.xml" ] }, "presentationLink": { "local": [ "alna-20220823_pre.xml" ] }, "schema": { "local": [ "alna-20220823.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20220823", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220823.htm", "contextRef": "C_50d14f33-0358-43c5-9ed6-589728c083ae", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220823.htm", "contextRef": "C_50d14f33-0358-43c5-9ed6-589728c083ae", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220823/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0000950170-22-017733-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-017733-xbrl.zip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end